Cysteinyl leukotrienes in allergic inflammation: Strategic target for therapy

William Busse, Monica Kraft

Research output: Contribution to journalReview article

124 Citations (Scopus)

Abstract

Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.

Original languageEnglish (US)
Pages (from-to)1312-1326
Number of pages15
JournalCHEST
Volume127
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Leukotriene Antagonists
Asthma
Inflammation
Muscle Contraction
Chemokines
Eosinophils
Smooth Muscle
Cell Survival
Stem Cells
Fibroblasts
Cytokines
Therapeutics
cysteinyl-leukotriene
Allergic Rhinitis

Keywords

  • Asthma
  • Cytokines
  • Eosinophils
  • Inflammation
  • Leukotriene receptor antagonists
  • Leukotrienes
  • Remodeling
  • Rhinitis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Cysteinyl leukotrienes in allergic inflammation : Strategic target for therapy. / Busse, William; Kraft, Monica.

In: CHEST, Vol. 127, No. 4, 04.2005, p. 1312-1326.

Research output: Contribution to journalReview article

@article{d1c9beb740884a5387da0f62319a0ba2,
title = "Cysteinyl leukotrienes in allergic inflammation: Strategic target for therapy",
abstract = "Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.",
keywords = "Asthma, Cytokines, Eosinophils, Inflammation, Leukotriene receptor antagonists, Leukotrienes, Remodeling, Rhinitis",
author = "William Busse and Monica Kraft",
year = "2005",
month = "4",
doi = "10.1378/chest.127.4.1312",
language = "English (US)",
volume = "127",
pages = "1312--1326",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - Cysteinyl leukotrienes in allergic inflammation

T2 - Strategic target for therapy

AU - Busse, William

AU - Kraft, Monica

PY - 2005/4

Y1 - 2005/4

N2 - Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.

AB - Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.

KW - Asthma

KW - Cytokines

KW - Eosinophils

KW - Inflammation

KW - Leukotriene receptor antagonists

KW - Leukotrienes

KW - Remodeling

KW - Rhinitis

UR - http://www.scopus.com/inward/record.url?scp=19044376965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19044376965&partnerID=8YFLogxK

U2 - 10.1378/chest.127.4.1312

DO - 10.1378/chest.127.4.1312

M3 - Review article

C2 - 15821210

AN - SCOPUS:19044376965

VL - 127

SP - 1312

EP - 1326

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -